Navigation Links
Hemostemix Meets with Newly Formed Clinical Trial Steering Committee

Toronto, Ontario (PRWEB) December 20, 2013

Hemostemix Ltd. announced today the formation and inaugural meeting of a clinical trial steering committee to guide the company in optimizing all aspects of the upcoming Phase 2 trial for its lead product, ACP-01, in patients with critical limb ischemia.

As well-respected specialists in critical limb ischemia and vascular surgery, the role of the Clinical Trial Steering Committee will be to advise the Company on all matters critical to the trial’s success.

“We are extremely honored with the caliber of key opinion leaders who have committed to providing us with their expertise on the trial’s design, implementation, sites, enrollment criteria, and several other critical parameters,” stated Hemostemix Founder and President, Dr. Valentin Fulga.

“We believe we have a real opportunity to learn valuable lessons from the committee’s collective experience in the space and translate that into a successful trial. The committee is providing valuable input in this regard,” continues Dr. Fulga, “and we were pleased to have what proved to be a very valuable inaugural meeting this week in Toronto.”

The committee is comprised of prominent clinician scientists, namely:

  •     Mohammed Al-Omran, MD is Professor of Surgery at University of Toronto and King Saud University and Chief of Vascular Surgery Division at St Michael’s Hospital. Dr. Al-Omran is a clinician investigator and currently appointed as a Scientist at the Li Ka Shing Knowledge Institute of St. Michael’s Hospital. His research interests are focused on atherosclerosis bench to bedside with special interest in peripheral arterial disease.
  •     Elmar R. Burchardt, MD, PhD, DS., is Professor of Clinical Pharmacology at the University of Witten in Germany. Dr. Burchardt has over 20 years of academic and industry experience in the areas of cell therapy, hematology, inflammation and cardiovascular diseases. He has designed and completed over 40 clinical trials with cell therapy and biological products in North America, Europe and other regions of the world, resulting in several marketing authorizations- As Vice President, Elmar initiated and successfully completed Aastrom Bioscience’s US-based phase II clinical cell therapy trials in Critical Limb Ischemia and Dilated Cardiomyopathy.
  •     York N. Hsiang, MB. ChB, MHS., FRCSC, is Professor of Vascular Surgery at the University of British Columbia and Consultant Surgeon at the Vancouver General Hospital, Vancouver, B.C. He has been the Professor of Surgery at the University of British Columbia in the Division of Vascular Surgery since July 2000. Dr. Hsiang has Specialty Board Qualifications in General Surgery (FRCSC 1986), Special Competence in Vascular Surgery (1987), and MHSc. (Clinical Epidemiology and Biostatistics, UBC, 1987-88).
  •     Thomas F. Lindsay, MD is Professor of Surgery and Chair of the Division of Vascular Surgery at the University of Toronto. He is head of the Division of Vascular Surgery within the Peter Monk Cardiac Center at University Health Network and Chair of the Royal College of Physicians and Surgeon of Canada Vascular Surgery Specialty Committee.
  •     Mark Jay Zucker, MD, JD, FACC, FAC is the Company’s Scientific Advisory Board representative on the clinical steering committee. Dr. Zucker is Director of the Harvey and Georgina Weinstein National Heart Transplant Center at Newark Beth Israel Medical Center and Clinical Professor of Medicine at the University of Medicine and Dentistry of New Jersey, New Jersey Medical School, Newark, N.J. He has been a principal or co-investigator on more than 40 trials including trials of cell-based therapies such as the BioHeart myoblast trial and the Baxter RENEW trial.

The steering committee meeting was lead by Company Founder and President, Dr. Valentin Fulga, with critical support and participation from the company’s new Medical Director, Dr. Eli Braude.

About Hemostemix Ltd
Hemostemix Ltd is a Canadian-Israeli company developing and commercializing innovative blood-derived cell therapies for medical conditions not adequately addressed by current treatments with an operating research, development and manufacturing facility in Kiryat Weizmann Science Park, Ness Ziona. For more information see

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Hemostemix Hosts Cell Therapy Industry Seminar
2. Hemostemix Announces Formation of Scientific Advisory Board
3. Hemostemix Announces US Patent Allowance
4. The Hemostemix Group of Companies Provides Corporate Strategy Update
5. What can happen when graphene meets a semiconductor
6. Discovery Meets Recovery in New Cedars-Sinai’s Advanced Health Sciences Pavilion Designed by HOK
7. Marken Meets Critical Demand For In Vitro Lab Shipments
8. SPIE ‘gold’ open access program meets new needs of UK authors -- and others
9. Origami meets chemistry in scholarly video-article
10. Veridiams Training Program Wins Accolades and Awards- Meets Skilled Labor Challenge Head On
11. Human Genome Decoder and Artificial Life Creator, J. Craig Venter to Speak at "The Atlantic Meets the Pacific"
Post Your Comments:
(Date:11/24/2015)... DIEGO , Nov. 24, 2015 Halozyme Therapeutics, Inc. ... Healthcare Conference in New York on Wednesday, ... Helen Torley , president and CEO, will provide a corporate ... New York at 1:00 p.m. ET/10:00 a.m. PT ... and investor relations, will provide a corporate overview. --> ...
(Date:11/24/2015)... /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: AEZ) (the ... the Toronto Stock Exchange, confirms that as of the ... developments that would cause the recent movements in the ... --> About Aeterna Zentaris Inc. ... Aeterna Zentaris is a specialty biopharmaceutical company engaged in ...
(Date:11/24/2015)... ... ... The Academy of Model Aeronautics (AMA), led by its Executive Council, has officially ... to represent the First–Person View (FPV) racing community. , FPV racing has exploded in ... racing and several new model aviation pilots have joined the community because of their ...
(Date:11/24/2015)... , Nov. 24, 2015 /PRNewswire/ - Aeterna ... announced today that the remaining 11,000 post-share consolidation ... Purchase Warrants (the "Series B Warrants") subject to ... exercised on November 23, 2015, which will result ... After giving effect to the issuance of such ...
Breaking Biology Technology:
(Date:10/26/2015)... , October 26, 2015 /PRNewswire/ ... --> adds Biometrics ... to 2021 as well as Emerging ... research reports to its collection of ... . --> ...
(Date:10/23/2015)... 23, 2015 Research and Markets ( ... Voice Recognition Biometrics Market 2015-2019" report to their ... The global voice recognition biometrics market to grow ... --> --> The report, ... based on an in-depth market analysis with inputs from ...
(Date:10/22/2015)... JOSE, Calif., Oct. 22, 2015  Synaptics (NASDAQ: SYNA ), ... for its first quarter ended September 30, 2015. ... quarter of fiscal 2016 grew 66 percent over the comparable quarter ... of fiscal 2016 was $23.8 million, or $0.62 per diluted share. ... income for the first quarter of fiscal 2016 grew 39 percent ...
Breaking Biology News(10 mins):